Clerk of the House of Representatives Legislative Resource Center 135 Cannon Building Washington, DC 20515 http://lobbyingdisclosure.house.gov Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510
<a href="http://www.senate.gov/lobby">http://www.senate.gov/lobby</a>

## **LOBBYING REPORT**

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Organization/Lobbying Firm Self Employed JOHNSON & JOHNSON SERVICES, INC.	ł Individual			
2. Address Address1 ONE JOHNSON & JOHNSON PLAZA	A.1			
	Address2			
City NEW BRUNSWICK State	NJ Zip Code <u>08933</u>	Country <u>USA</u>		
3. Principal place of business (if different than line 2)				
City State	Zip Code	Country		
4a. Contact Name b. Telephone N	umber c. E-mail	5. Senate ID# 20686-12		
7. Client Name Self Check if client is a state or local government or instrumentality  JOHNSON & JOHNSON SERVICES, INC.  6. House ID# 303480000				
9. Check if this filing amends a previously filed version of this report	Q2 (4/1 - 6/30) Q3 (7/1 - 9/30) Q3 (7/1 - 9/30	Q4 (10/1 - 12/31)		
INCOME OR EXPENSES - YOU	MUST complete either Line 12 or Line 1	13		
12. Lobbying	13. Organizations			
<b>INCOME</b> relating to lobbying activities for this reporting period was:	<b>EXPENSE</b> relating to lobbying activities for this re-	porting period were:		
<u>Less than \$5,000</u>	<u>Less than \$5,000</u>			
\$5,000 or more \$	\$5,000 or more			
Provide a good faith estimate, rounded to the nearest \$10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	<b>14. REPORTING</b> Check box to indicate expense as See instructions for description of options.	ecounting method.		
	Method A. Reporting amounts using LDA defin	nitions only		
	Method B. Reporting amounts under section 60 Internal Revenue Code	033(b)(8) of the		
	Method C. Reporting amounts under section 16 Revenue Code	52(e) of the Internal		
Signature Digitally Signed By: Jane Adams	Da	1/22/2024 12:32:15 PM		

https://disclosurespreview.house.gov/ld/ldxmlrelease/2023/Q4/301536979.xml

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

Issues related to:

- Contact lens safety, peripheral artery disease, and stroke care, specifically to provisions regarding appropriations report language

- Appropriations for Labor Health and Human Services

	peripheral artery disease, and stroke abor Health and Human Services	care, specifically to provis	ions regarding appropriations report language	
17. House(s) of Congr	ess and Federal agencies  Check	if None		
U.S. SENATE, U.S. H	OUSE OF REPRESENTATIVES			
18. Name of each indi	vidual who acted as a lobbyist in this	s issue area		
First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Deana	McRae			
Timothy	Swope			
Leif	Brierley			
Larry	Camm			
Jane	Adams			
Colleen	Vivaldi			
				-

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

- 15. General issue area code HCR
- 16. Specific lobbying issues

L	. 💉	13/5/HR	X 3(1)	"HELP	Conave	a Act"	, regarding	all	nrovicions
Г		13/3/1110	. 050,		Copay	JAICE .	, regarding	an	provisions

- PL 117-169, "The Inflation Reduction Act", regarding provisions impacting drug pricing and implementation
- PL 113-5 "Pandemic All Hazards Preparedness Reauthorization", regarding all provisions
- S 1355/HR 2940, "PASTEUR Act", regarding all provisions
- HR 3723, "Medical Device Electronic Labeling Act", regarding all provisions
- HR 2748, "Contact Lens Prescription Verification Modernization Act", regarding all provisions
- HR 4261, "Amputation Reduction and Compassion Act", regarding all provisions
- S 3131/HR 5539, "ORPHAN Cures Act", regarding all provisions
- HR 5372, "Expanding Access to Seniors Access to Lower Cost Medicines Act of 2023", regarding all provisions
- S 2305, "The Biosimilar Red Tape Elimination Act", regarding all provisions
- HR 1352, "Increasing Access to Biosimilars Act of 2023", regarding all provisions

Issues related to:

- Obesity
- Biosimilars
- Health equity and diversity in clinical trials
- Myopia
- Ambulatory surgical services
- Access to sterilization capacity for medical technologies
- Peripheral artery disease
- Cardiovascular health
- Stroke care
- FDA medical device shortage reporting requirements
- Alternative funding programs
- 340B
- PBM practices
- Health care workforce wellbeing
- Medicaid Drug Rebate Program

17 House(s)	of Congress and	d Federal agencies	Check if None
1 / . 110usc(s)	of Congress and	u i cuciai agencies	CHECK II NOHE

## U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Deana	McRae			
Leif	Brierly			
Larry	Camm			
Timothy	Swope			
Riley	Swinehart			
Wendy	Sussman			
Meghan	Stone			
Amy	Pellegrino			
Kelly	Waters			
Emely	Sanchez			
Abigail	Pinkele			
Jane	Adams			
Colleen	Vivaldi			
David	Kavanagh			

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed. 15. General issue area code LBR 16. Specific lobbying issues - Issues related to diversity, equity and inclusion 17. House(s) of Congress and Federal agencies Check if None U.S. HOUSE OF REPRESENTATIVES, Federal Trade Commission (FTC) 18. Name of each individual who acted as a lobbyist in this issue area Last Name First Name Suffix Covered Official Position (if applicable) New Larry Camm 19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

	2	,	nformation as requested. Add additional page(s) as r	U
15. General issue area	code VET			
16. Specific lobbying is	ssues			
- Issues related to Vete	rans Administration and Veterans H	ealth Administration polic	ey, procurement, and contracting processes for medic	al technology
17. House(s) of Congre	ess and Federal agencies  Check	if None		
U.S. HOUSE OF REP	RESENTATIVES			
18. Name of each indiv	ridual who acted as a lobbyist in this	s issue area		
First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Riley	Swinehart			
Jane	Adams			
19. Interest of each for	eign entity in the specific issues liste	ed on line 16 above 💟 (	Check if None	
			<u> </u>	

			sue areas in which the registrant engaged in lobbying aformation as requested. Add additional page(s) as re-	
15. General issue area co	ode TRD			
16. Specific lobbying iss	ues			
Issues related to:  - Medical supply chains  - TRIPS Waiver				
17. House(s) of Congress	s and Federal agencies Chec	k if None		
U.S. SENATE, U.S. HO	USE OF REPRESENTATIVES			
18. Name of each individ	dual who acted as a lobbyist in th	is issue area		
First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Leif	Brierley			
Timothy	Swope			
David	Kavanaugh			
Jane	Adams			
Wendy	Sussman			
19. Interest of each forei	gn entity in the specific issues lis	ted on line 16 above C	heck if None	

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed. 15. General issue area code CSP 16. Specific lobbying issues Issues related to: Counterfeit healthcare goods Brand protection 17. House(s) of Congress and Federal agencies Check if None U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES 18. Name of each individual who acted as a lobbyist in this issue area Covered Official Position (if applicable) First Name Last Name Suffix New Leif Brierley 19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

Issues related to:	ntelligence Research, Innovation, an	nd Accountability Act, rega	arding all provisions	
- Data privacy				
- Cybersecurity - Artificial intelligence				
17. House(s) of Congr		c if None		
U.S. SENATE, U.S. F	IOUSE OF REPRESENTATIVES			
U.S. SENATE, U.S. F. 18. Name of each indi	vidual who acted as a lobbyist in thi	s issue area		
		s issue area Suffix	Covered Official Position (if applicable)	New

Adams

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed. 15. General issue area code CPT 16. Specific lobbying issues - S 150, "Affordable Prescriptions for Patients Act of 2023", regarding all provisions S 79/HR 1717, "Interagency Patent Coordination and Improvement Act of 2023", regarding all provisions - Issues related to intellectual property 17. House(s) of Congress and Federal agencies Check if None U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES 18. Name of each individual who acted as a lobbyist in this issue area First Name Last Name Suffix Covered Official Position (if applicable) New Timothy Swope David Kavanaugh

Jane

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

1//	٠. ٢			
16. 3	Specific	: lobb	vıng	issues

C 966/HD 2672 "Amon	ican Innovation and D&D Compati	tiveness Act of 2022 " ma	anding provisions related to research & dayslanman	t avnancina
Issues related to:	ican innovation and R&D Competi	uiveness Act of 2025", re	garding provisions related to research & development	t expensing
	lobal tax & implementation			
- R&D expensing	iodai tax & implementation			
- Corporate tax provision	ons in TCJA			
	Minimum Tax implementation			
	ss and Federal agencies   Check			
U.S. HOUSE OF REPR	RESENTATIVES, Treasury - Dept of	of		
18. Name of each indivi	idual who acted as a lobbyist in this	s issue area		
First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
David	Kavanaugh			
Jane	Adams			
Kelly	Waters			
Riley	Swinehart			
19. Interest of each fore	ign entity in the specific issues liste	ed on line 16 above	Check if None	•

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed. 15. General issue area code PHA 16. Specific lobbying issues - HR 4490, "To amend the Controlled Substances Act to authorize pharmacies to deliver certain controlled substances to an administering practitioner in lieu of delivering such substances to the to the ultimate user, and for other purposes", regarding all provisions - Issues related to drug shortages 17. House(s) of Congress and Federal agencies Check if None U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES 18. Name of each individual who acted as a lobbyist in this issue area First Name Last Name Suffix Covered Official Position (if applicable) New Amy Pellegrino Riley Swinehart Wendy Sussman Meghan Stone Abigail Pinkele Timothy Swope 19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed. 15. General issue area code ENV 16. Specific lobbying issues Issues related to Clean energy Environmental sustainability 17. House(s) of Congress and Federal agencies Check if None U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES 18. Name of each individual who acted as a lobbyist in this issue area Covered Official Position (if applicable) First Name Last Name Suffix New Kelly Waters 19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed. 15. General issue area code BNK 16. Specific lobbying issues Issues related to: Chapter 11 corporate bankruptcy process - Litigation reform 17. House(s) of Congress and Federal agencies Check if None U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES 18. Name of each individual who acted as a lobbyist in this issue area First Name Last Name Suffix Covered Official Position (if applicable) New Riley Swinehart Kelly Waters Abigail Pinkele Larry Camm Jane Adams 19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of

			ssue areas in which the registrant engaged in a formation as requested. Add additional pages.	
15. General issue area co	de MMM			
16. Specific lobbying issu	ues			
Issues related to the Med	licaid Drug Rebate Program			
17. House(s) of Congress	s and Federal agencies Che	eck if None		
U.S. SENATE, U.S. HOU	USE OF REPRESENTATIVES			
18. Name of each individ	lual who acted as a lobbyist in t	his issue area		
First Name	Last Name	Suffix	Covered Official Position (if applica	ble) New
Amy	Pellegrino			
19. Interest of each foreig	gn entity in the specific issues li	isted on line 16 above C	heck if None	
Information Update Pa	ge - Complete ONLY where r	egistration information has	changed.	
20. Client new address				
Address				
City		State	Zip Code	Country
21. Client new principal p	place of business (if different th	nan line 20)		
City		State _	Zip Code	Country
22. New General descript	tion of client's business or activ	vities		
LOBBYIST UPD	ATE			
23. Name of each previous	usly reported individual who is	no longer expected to act as	a lobbyist for the client	
First Name	Last Name	Suffix First	Name Last Name	Suffix
1				
2		4		
ISSUE UPDATE				
24. General lobbying issu	ue that no longer pertains			
AFFILIATED OF	RGANIZATIONS			
25. Add the following aff	filiated organization(s)			
Internet Address:				

/16/24, 12:18 PM LD-2 Disclosure Form					
Name	Address City State/Pro	ovince Zip Country		Principal Place of Bu (city and state or cou	
			City State	Countr	у
26. Name of each previously reported	organization that is no longer affiliate	ed with the registrant or client			
1	2	3			
FOREIGN ENTITIES					
27. Add the following foreign entities	:				
Name	Address Street Address City State/Province Country	Principal place of busine (city and state or country)		Amount of contribution for lobbying activities	Ownership percentage in client
		City State Country			%
28. Name of each previously reported	foreign entity that no longer owns, or	controls, or is affiliated with	the regis	trant, client or affiliate	d organization
1 2	<u>3</u> <u>4</u>	<u>5</u>			
CONVICTIONS DISCLO	SURE				
29. Have any of the lobbyists listed on an illegal kickback, tax evasion, fraud No Yes					embezzlement,

Description of Offense(s)

Lobbyist Name